Low-molecular-weight heparin is named as a drug or biological intervention in 2 clinical trials in our Ireland, UK, USA and China trial registers, 2 of which are recruiting. Lead sponsors include University of Calgary (1) and Janssen Research & Development, LLC (1). Registered phases: Phase 3 and Phase 2. Conditions studied include Venous Thromboembolism; Postpartum Period; Aspirin.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06494878 | The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity (ClinicalTrials.gov ↗) Venous Thromboembolism, Postpartum Period, Aspirin |
Phase 3 | Recruiting |
| NCT05498428 | A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗) Carcinoma, Non-small-Cell Lung |
Phase 2 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Venous Thromboembolism | 1 |
| Postpartum Period | 1 |
| Aspirin | 1 |
| Low Molecular Weight Heparin | 1 |
| Carcinoma, Non-small-Cell Lung | 1 |
| Lead sponsor | Trials |
|---|---|
| University of Calgary | 1 |
| Janssen Research & Development, LLC | 1 |
| Register | Low-molecular-weight heparin trials |
|---|---|
| Clinical trials in Ireland | 1 |
| Clinical trials in UK | 1 |
| Clinical trials in USA | 1 |
| Clinical trials in China | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Low-molecular-weight heparin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Low-molecular-weight heparin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.